news New class of CAR T cells combat previously “untargetable” cancer drivers 4 November 2021 | By Anna Begley (Drug Target Review) The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
news Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction 4 November 2021 | By Anna Begley (Drug Target Review) ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news Moderna and Metagenomi to develop in vivo gene therapies 3 November 2021 | By Anna Begley (Drug Target Review) Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
podcast Episode 3 – Cell & gene therapy with Dr Sam Wadsworth, Ultragenyx Pharmaceutical & Dr Eric Ostertag, Poseida Therapeutics 1 November 2021 | By Drug Target Review Tune in to this podcast to learn about AAV vectors for gene therapy delivery and engineering CAR T cells against solid tumours.
news GLP-1 and GIP receptor agonists reduce mouse obesity in pre-clinical study 1 November 2021 | By Anna Begley (Drug Target Review) Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
video Engineering better CAR T cells with Professor Ann Ager, Cardiff University 27 October 2021 | By Drug Target Review Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
news Specific mechanism found to control transition from acute to chronic pain 27 October 2021 | By Anna Begley (Drug Target Review) A new study is the first to identify N-acylethanolamine acid amidase as a new drug target to treat different forms of chronic pain.
news Gene therapy shows promise for Angelman syndrome treatment 26 October 2021 | By Anna Begley (Drug Target Review) A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
article Peptides: a promising alternative to opioids for chronic pain relief 25 October 2021 | By Anna Begley (Drug Target Review), Anton Simeonov, Victoria Rees (Drug Target Review) In an exclusive with Drug Target Review, researchers at the University at Buffalo explain how they developed a novel peptide that could be a future treatment for chronic inflammatory pain.
news $2.6 million granted to create pan-coronavirus vaccine 25 October 2021 | By Anna Begley (Drug Target Review) The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
news Novel strategy successfully suppresses HIV infection in mice 25 October 2021 | By Anna Begley (Drug Target Review) A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
news $7.5 million to fund senescent cell research for age-related disease 22 October 2021 | By Anna Begley (Drug Target Review) Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
news Novel method refines cryogenic electron microscopy (cyro-EM) 21 October 2021 | By Anna Begley (Drug Target Review) The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
news Highly potent antiviral against dengue could prevent spread of virus 18 October 2021 | By Victoria Rees (Drug Target Review) A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
news Mission Therapeutics receives $500k grant for Parkinson’s research 14 October 2021 | By Anna Begley (Drug Target Review) Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
